AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.05

+1.7%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$898.69M
EPS-1.7400
P/E Ratio-5.20
Earnings Date08/12/2026

spry

EPS

Last Annual Value

-1.74

3-Year CAGR

-26%

5-Year CAGR

-124%

10-Year CAGR

-13%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of EPS

SPRY · NASDAQ
CompanyEPS
CAGR 3Y
CAGR 5Y
CAGR 10Y
-1.74
N/AN/AN/A 
-0.17
N/AN/AN/A
SVRA logo
Savara Inc.
NASDAQ:SVRA
-0.53
N/AN/AN/A
-3.18
N/AN/AN/A
-3.71
N/AN/AN/A
-2.85
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
-0.52
N/AN/AN/A
-2.01
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
-0.98
N/AN/AN/A
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.05, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.05